Connect Biopharma Holdings (CNTB) Operating Income (2024 - 2026)

Connect Biopharma Holdings has disclosed Operating Income across 3 years of filings, most recently posting -$17.6 million for Q2 2026.

• In Q2 2026, Operating Income fell 31.14% year-over-year to -$17.6 million; the TTM figure through Jun 2026 stood at -$70.4 million (down 45.68% YoY), while the FY2025 annual figure was -$58.1 million, down 158.66% from the prior year.
• Operating Income came in at -$17.6 million for Q2 2026 at Connect Biopharma Holdings, up from -$19.6 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $13.6 million in Q2 2024 to a low of -$19.6 million in Q1 2026.
• Average Operating Income over 3 years is -$11.8 million, with a median of -$13.6 million recorded in 2024.
• The largest YoY upside for Operating Income was 9.39% in 2025 against a maximum downside of 198.37% in 2025.
• Over 3 years, Operating Income stood at -$9.6 million in 2024, then plunged by 61.41% to -$15.5 million in 2025, then decreased by 13.38% to -$17.6 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$17.6 million in Q2 2026, -$19.6 million in Q1 2026, and -$15.5 million in Q4 2025.